Clinical Trial

A Study of Telitacicept for IgA Nephropathy (TELIGAN)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 16, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the efficacy and safety of Telitacicept in patients with primary IgA nephropathy at risk of progressing to end-stage renal disease(ESRD), despite maximum tolerated treatment with renin-angiotensin system(RAS) blockade using angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II type I receptor blockers (ARBs).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-03-22; most recent amendment 2025-12-08.
Status change: Recruiting → Active, Not Recruiting 2024-09-12
Status change: Not Yet Recruiting → Recruiting 2023-09-01
Trial Details
NCT Number NCT05799287
Lead Sponsor RemeGen Co., Ltd.
Conditions Primary IgA Nephropathy
Enrollment 318 participants
Start Date 2023-04-28
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-12-16